Testosterone and blood pressure: the FDA warning after TRAVERSE
FDA's review found no increase in major cardiovascular events in TRAVERSE's studied population, yet ambulatory-monitoring studies showed a blood-pressure rise and prompted classwide label changes. Those are different outcomes.
Testosterone therapy can raise blood pressure, and FDA required classwide blood-pressure information after reviewing ambulatory-monitoring studies. That finding is separate from FDA’s conclusion that the TRAVERSE trial did not show an increased rate of major adverse cardiovascular events in its studied population, which supported removal of an older boxed-warning statement. “No MACE increase in TRAVERSE” does not mean “no blood-pressure effect,” and a small average BP change does not predict one person’s result.12
The distinction matters at a hormone clinic because a headline may cite the boxed-warning change while omitting the newly emphasized measurement. A responsible program can explain both records without treating blood pressure as a proxy for every cardiovascular outcome.
Two FDA conclusions, two different endpoints
| Evidence | Outcome measured | What it does not prove |
|---|---|---|
| TRAVERSE cardiovascular trial, as evaluated by FDA | Major adverse cardiovascular events in a specified population over the trial period | That BP never rises or that all populations/routes have identical risk |
| Ambulatory BP studies | Average 24-hour pressure change under studied products | That a heart attack or stroke occurred because of that measured change |
| A patient's office reading | One measurement in a particular context | That testosterone caused the value or that the trend is settled |
FDA’s class action removed language suggesting an increased MACE risk from the boxed warning and required labeling about increased blood pressure. These actions can both be scientifically coherent because an intermediate measurement and a clinical event are not the same endpoint. Neither action approves testosterone for generic energy, aging, athletic or weight-loss goals.13
What the ambulatory study contributes
An original study measured 24-hour blood pressure rather than relying only on clinic readings. Among 169 men in the primary week-16 analysis of a 246-person testosterone-gel study, mean 24-hour systolic pressure rose by about 1.9 mmHg. That group average is relevant to a label warning, but it does not mean each participant had the same change or that a two-millimeter office reading diagnoses a drug effect.2
The study’s gel formulation, population, measurement method and follow-up should stay attached to its number. Extrapolating the exact mean to an injection, pellet, compounded preparation or person with different baseline health would overstate the evidence. The current label for the exact dispensed product remains the product-level reference.
A monitoring conversation needs ownership
Before a prescription or refill program, ask who records baseline blood pressure, what measurements the team regards as comparable, who reviews a changed value, and how the response is communicated. This is not a request for an online threshold or self-directed medicine change. It is a way to see whether a practice has a real follow-up path.
Pressure can vary with measurement technique, other medicines, illness, sleep, alcohol, stress and existing hypertension. A clinician interprets the pattern with the broader history. If a practice automatically attributes every rise to testosterone—or dismisses it because a MACE warning changed—it has skipped that assessment.
The testosterone-clinic question guide covers diagnosis and the full monitoring program. Hematocrit monitoring concerns a different laboratory signal; it should not substitute for a blood-pressure plan. Both may be relevant, but neither is a summary of the other.
At a hormone-therapy practice, look for an answer that names the current FDA action, the measured endpoint and the clinician responsible for follow-up. That is more useful than declaring testosterone categorically heart-safe or heart-dangerous.
Sources
- U.S. Food and Drug Administration. FDA issues class-wide labeling changes for testosterone products. FDA separates TRAVERSE's major-adverse-cardiovascular-event conclusion from classwide ambulatory blood-pressure findings and required label wording. Accessed .
- PubMed / original ambulatory blood-pressure study. Ambulatory blood pressure after testosterone gel in men with hypogonadism. Original 16-week study measured 24-hour systolic pressure and observed a mean increase under the studied gel protocol; it is not a heart-attack outcome trial. Accessed .
- U.S. Food and Drug Administration. Testosterone information. Current FDA product-indication and labeling context; a removed warning does not create a general wellness indication. Accessed .